Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand×Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-resistant B-precursor Acute Lymphoblastic Leukemia in Mice

EBioMedicine

Volumn 2, Issue 4, 2015, Pages 306-316

  Uckun, Fatih M ^a,b,c   Myers, Dorothea E ^a   Ma, Hong ^a   Rose, Rebecca ^d   Qazi, Sanjive ^a,e  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Rose Pathology Services   (United States)

^e GUSTAVUS ADOLPHUS COLLEGE   (United States)

Author keywords

Bone marrow transplantation; Cancer; Leukemia; Personalized medicine; Precision medicine; Radiation resistance; Total body irradiation

Indexed keywords

ASPARAGINASE MACROGOL; CD19 LIGAND; DEXAMETHASONE; HYBRID PROTEIN; IMATINIB; LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; TRANSGENIC MOUSE; WESTERN BLOTTING; WHOLE BODY RADIATION;

EID: 84949550927     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.02.008     Document Type: Article

References (33)

1. Asselin B.L., Gaynon P., Whitlock J.A. Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion. Curr. Opin. Oncol. 2013, (Suppl. 3):S1-S13. (quiz S14-6). 10.1097/CCO.0000000000000017.
2. Bachanova V., Burke M.J., Yohe S., Cao Q., Sandhu K., Singleton T.P., Brunstein C.G., Wagner J.E., Verneris M.R., Weisdorf D.J. Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. Biol. Blood Marrow Transplant. 2012, 18:963-968.
3. Balduzzi A., Di Maio L., Silvestri D., Songia S., Bonanomi S., Rovelli A., Conter V., Biondi A., Cazzaniga G., Valsecchi M.G. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukemia: is there any room for intervention. Br. J. Haematol. 2014, 164:396-408.
4. Bar M., Wood B.L., Radich J.P., Doney K.C., Woolfrey A.E., Delaney C., Appelbaum F.R., Gooley T.A. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leukemia Res.Treat. 2014, (Article ID: 421723). 10.1155/2014/421723.
5. Bernard F., Auquier P., Herrmann I., Contet A., Poiree M., Demeocq F., Plantaz D., Galambrun C., Barlogis V., Berbis J., Garnier F., Sirvent N., Kanold J., Chastagner P., Chambost H., Michel G. Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study. Bone Marrow Transplant. 2014, 49:709-716. (Epub 2014 Feb 17). 10.1038/bmt.2014.3.
6. Bremer E. Targeting of the tumor necrosis receptor superfamily for cancer immunotherapy. 2013, (Review Article), ISRN Oncology., (Article ID: 371854). 10.1155/2013/371854.
7. D'Cruz O.J., Uckun F.M. Novel mAb-based therapies for leukemia. Future Medicine 2013, 54-77. Future Medicine Ltd, London. 10.2217/ebo.13.218. F.M. Uckun (Ed.).
8. Dimberg L.Y., Anderson C.K., Camidge R., Behbakht K., Thorbum A., Ford H.L. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2013, 32(11):1341-1350. 10.1038/onc.2012.164.
9. Fox N.L., Humphreys R., Luster T.A., Klein J., Gallant G. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy. Expert. Opin. Biol. Ther. 2010, 10(1):1-18. 10.1038/sj.bjc.6605987.
10. Gaynon P.S., Harris R.E., Altman A.J., Bostrom B.C., Brenneman J.C., Hawks R., Steele D., Zipf T., Stram D.O., Villaluna D., Trigg M.E. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12months of the completion of primary therapy: Children's Oncology Group Study CCG-1941. J. Clin. Oncol. 2006, 24:3150-3156.
11. Gong B., Almasan A. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res. 2000, 60(20):5754-60.
12. Kalaycio M., Bolwell B., Rybicki L., Absi A., Andresen S., Pohlman B., Dean R., Sobecks R., Copelan E. BU- vs TBI-based conditioning for adult patients with ALL. Bone Marrow Transplant. 2011, 46:1413-1417.
13. Kruyt F.A.E. TRAIL and cancer therapy. Cancer Lett. 2008, 263:14-25.
14. Locatelli F., Schrappe M., Bernardo M.E., Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012, 120:2807-2816. 10.1182/blood-2012-02-265884.
15. Marks D.I., Forman S.J., Blume K.G., et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol. Blood Marrow Transplant. 2006, 12:438-453.
16. Merino D., Lalaoui N., Morizot A., Solary E., Micheau O. TRAIL in cancer therapy: present and future challenges. Expert Opin. Ther. Targets 2007, 11:1299-1314.
17. Mori T., Aisa Y., Kato J., Yamane A., Nakazato T., Shigematsu N., Okamoto S. Safety and efficacy of total body irradiation, cyclophosphamide, and cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Am. J. Hematol. 2012, 87:349-353.
18. Pulsipher M.A., Bader P., Klingebiel T., Cooper L.J. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol. Blood Marrow Transplant. 2009, 15:62-71.
19. Tracey J., Zhang M.J., Thiel E., Sobocinski K.A., Eapen M. Transplantation conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia. Biol. Blood Marrow Transplant. 2013, 19:255-259.
20. Uckun F.M., Jaszcz W., Ambrus J.L., Fauci A.S., Gajl-Peczalska K., Song C.W., Wick M.R., Myers D.E., Waddick K., Ledbetter J.A. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 1988, 71:13-29.
21. Uckun F.M., Jaszcz W., Chandan-Langlie M., Waddick K.G., Gajl-Peczalska K., Song C.W. Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia. J. Clin. Invest. 1993, 91:1044-1051.
22. Uckun F.M., Kersey J.H., Haake R., Weisdorf D., Nesbit M.E., Ramsay N.K. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. N. Engl. J. Med. 1993, 329(18):1296-1301.
23. Uckun F.M., Qazi S., Ma H., Tuel-Ahlgren L., Ozer Z. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(7):2902-2907.
24. Uckun F.M., Goodman P., Ma H., Dibirdik I., Qazi S. CD22 exon 12 deletion as a novel pathogenic mechanism of human B-precursor leukemia. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:16852-16857.
25. Uckun F.M., Dibirdik I., Qazi S. Augmentation of the anti-leukemic potency of total body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK). Radiat. Res. 2010, 174:526-531.
26. Uckun F.M., Sun L., Qazi S., Ma H., Ozer Z. Recombinant human CD19-ligand protein as a potent anti-leukemic agent. Br. J. Haematol. 2011, 153:15-23.
27. Uckun F.M., Qazi S., Ozer Z., Garner A.L., Pitt J., Ma H., Janda K.D. Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. Br. J. Haematol. 2011, 153:741-752.
28. Uckun F.M., Ma H., Zhang J., Ozer Z., Dovat S., Mao C., Ishkhanian R., Goodman P., Qazi S. Serine phosphorylation by SYK is critical for nuclear localization and transcription factor function of Ikaros. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:18072-18077.
29. Uckun F.M., Qazi S., Cely I., Sahin K., Shahidzadeh A., Ozercan I., Yin Q., Gaynon P., Termuhlen A., Cheng J., Yiv S. Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. Blood 2013, 121:4348-4354.
30. Uckun F.M., Qazi S., Ma H., Yin L., Cheng J. A rationally designed CD22δE12-siRNA nanoparticle for RNAi therapy in B-lineage lymphoid malignancies. EBioMed. 2014, 1:141-155.
31. Uckun F.M., Myers D.E., Qazi S., Ozer Z., Rose R., D'Cruz O., Ma H. Recombinant human CD19L-sTRAIL effectively targets B-cell precursor acute lymphoblastic leukemia. J. Clin. Invest. 2015, 10.1172/JCI76610.
32. Uckun F.M., Ma H., Cheng J., Myers D.E., Qazi S. CD22δE12 as a molecular target for RNAi therapy. Br. J. Haematol. 2015, 10.1111/bjh.13306.
33. Wissink E.H., Verbrugge I., Vink S.R., Schader M.B., Schaefer U., Walczak H., Borst J., Verheij M. TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiother. Oncol. 2006, 80:214-222.